In the battle against HIV/AIDS conditions on the frontlines are constantly in flux as treatment, research and policy evolve. The landmark HIV Prevention Trials Network (HPTN) 052 study, which established that antiretroviral treatment in people who are HIV positive decreases the likelihood of transmitting HIV to their sexual partners, was no exception...
read more
Science named the HIV Prevention Trials Network (HPTN) 052 study "Breakthrough of the Year." FHI 360 congratulates our HPTN 052 collaborating partners on this important achievement. This is the second year in a row that Science sele... Read Post
When the HIV Prevention Trials Network (HPTN) 052 investigators released their landmark study results last year showing that treatment can reduce HIV transmission by 96% in serodiscordant couples, questions were raised about the cos... Read Post
Study results released by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes. Expanded analysis of HPTN 052 study data, presented at the XIX International... Read Post